Bio­Marin spells out a trou­bling slide in Fac­tor VI­II lev­els for its big block­buster con­tender val­rox

We al­ready knew from Bio­Marin’s state­ment a few days ago that their gene ther­a­py for he­mo­phil­ia A con­tin­ued to pro­tect pa­tients against the bleed­ing …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.